Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.
Video content above is prompted by the following:
Concerning access to these oral chemotherapy options, how do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will impact access to these metastatic colorectal cancer therapies starting in 2025?
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More